Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24996772)

1.

The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies.

Schneider M, Korzeniewski N, Merkle K, Schüler J, Grüllich C, Hadaschik B, Hohenfellner M, Duensing S.

Urol Oncol. 2015 Feb;33(2):72.e1-7. doi: 10.1016/j.urolonc.2014.06.001. Epub 2014 Jul 2.

PMID:
24996772
2.

Prostate cancer: Promising combination treatment for prostate cancer.

[No authors listed]

Nat Rev Urol. 2015 Jun;12(6):302. doi: 10.1038/nrurol.2015.118. Epub 2015 May 19. No abstract available.

PMID:
25986761
3.

Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.

Henk HJ, Woloj M, Shapiro M, Whiteley J.

Clin Ther. 2015 Jan 1;37(1):124-33. doi: 10.1016/j.clinthera.2014.10.019. Epub 2014 Nov 22.

PMID:
25467191
4.

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U.

Leuk Lymphoma. 2015 Jan 14:1-11. [Epub ahead of print]

PMID:
25393806
5.

Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.

Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.

Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014.

6.

Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.

Weigel MT, Rath K, Alkatout I, Wenners AS, Schem C, Maass N, Jonat W, Mundhenke C.

Oncology. 2014;87(4):232-45. doi: 10.1159/000363656. Epub 2014 Aug 8.

PMID:
25116401
7.

Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.

Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H.

Biol Pharm Bull. 2014;37(8):1330-5.

8.

Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.

Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R.

Clin Transl Oncol. 2015 Feb;17(2):145-51. doi: 10.1007/s12094-014-1206-6. Epub 2014 Jul 25.

PMID:
25060568
9.

Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.

Jiang H, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang Q, Chen H, Chen YH, Han W, Zhang XH, Wang Y, Wang JZ, Wang FR, Qin YZ, Lai YY, Huang XJ.

Bone Marrow Transplant. 2014 Sep;49(9):1146-54. doi: 10.1038/bmt.2014.146. Epub 2014 Jul 21.

PMID:
25046218
10.

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Wu M, Yuan Y, Pan YY, Zhang Y.

Mol Med Rep. 2014 Aug;10(2):931-8. doi: 10.3892/mmr.2014.2243. Epub 2014 May 16.

PMID:
24840891
11.

Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.

Shiota M, Itsumi M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

Prostate. 2014 Jun;74(8):829-38. doi: 10.1002/pros.22799. Epub 2014 Apr 12.

PMID:
24729449
12.

Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.

Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.

JAMA. 2014 Apr 9;311(14):1430-7. doi: 10.1001/jama.2014.3314.

PMID:
24715074
13.
14.
15.

Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model.

Geisler K, Reischer A, Kroeger I, Jacobs B, Meinhardt K, Bauer R, Ryffel B, Mackensen A, Ullrich E.

Oncol Rep. 2014 May;31(5):2015-20. doi: 10.3892/or.2014.3070. Epub 2014 Mar 10.

PMID:
24626639
16.

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.

Breccia M, Alimena G.

Mediterr J Hematol Infect Dis. 2014 Jan 2;6(1):e2014003. doi: 10.4084/MJHID.2014.003. eCollection 2014 Jan 2. Review.

17.

Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.

Ding J, Romani J, Zaborski M, MacLeod RA, Nagel S, Drexler HG, Quentmeier H.

PLoS One. 2013 Dec 11;8(12):e83510. doi: 10.1371/journal.pone.0083510. eCollection 2013.

18.

Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.

Lin HP, Lin CY, Hsiao PH, Wang HD, Sheng Jiang S, Hsu JM, Jim WT, Chen M, Kung HJ, Chuu CP.

PLoS One. 2013 Dec 5;8(12):e82625. doi: 10.1371/journal.pone.0082625. eCollection 2013.

19.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
20.

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ.

Lancet Oncol. 2013 Dec;14(13):1307-16. doi: 10.1016/S1470-2045(13)70479-0. Epub 2013 Nov 8.

PMID:
24211163
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk